TAK-448 acetate

Cat. No.:	HY-P0076A				
CAS No.:	1470374-22	-1			
Molecular Formula:	C ₆₀ H ₈₄ N ₁₆ O ₁₆	i		HO	
Molecular Weight:	1285.41			-N-0°	
Sequence Shortening:	Ac-{d-Tyr}-{Hyp}-NTF-{Aza-Gly}-L-{Arg(Me)}-W-NH2				
Target:	Kisspeptin Receptor				
Pathway:	GPCR/G Protein				
Storage:	brage: Sealed storage, away from moisture				
	Powder	-80°C	2 years		
		-20°C	1 year		
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)				

SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 100 mg/mL (77.80 mM) H ₂ O : 50 mg/mL (38.90 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown.						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	0.7780 mL	3.8898 mL	7.7796 mL		
		5 mM	0.1556 mL	0.7780 mL	1.5559 mL		
		10 mM	0.0778 mL	0.3890 mL	0.7780 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (77.80 mM); Clear solution; Need ultrasonic						
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (1.94 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (1.94 mM); Clear solution						

BIOLO CICAL ACTIV					
Description	TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC ₅₀ of 460 pM and an EC ₅₀ of 632 pM ^[1] .				
IC₅₀ & Target	IC50: 460 pM (KISS1R) ^[1] EC50: 632 pM (KISS1R) ^[1]				

RedChemExpress



Product Data Sheet

In Vivo	TAK-448 acetate (0.01-3	TAK-448 acetate (0.01-3 mg/kg; given i.h.; dosings on day 0 and 28) has greater anti-tumor effects in VCaP xenograft model ^[2]			
	MCE has not independe	MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	Rat VCaP xenograft androgen-sensitive prostate cancer model (7-week-old rats)			
	Dosage:	0.01, 0.03, 0.3, 3 mg/kg			
	Administration:	Given i.h.; dosings on day 0 and 28			
	Result:	Had greater anti-tumor effects in VCaP xenograft model.			

REFERENCES

[1]. Nishizawa N, et al. Design and Synthesis of an Investigational Nonapeptide KISS1 Receptor (KISS1R) Agonist, Ac-d-Tyr-Hydroxyproline (Hyp)-Asn-Thr-Phe-azaGly-Leu-Arg(Me)-Trp-NH2 (TAK-448), with Highly PotentTestosterone-Suppressive Activity and Excellent Water Solubility. J Med Chem. 2016 Oct 13;59(19):8804-8811.

[2]. Ishikawa K,et al. Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model. Eur J Pharmacol. 2018 Jun 5;828:126-134.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA